Trazodone in Adolescents (Ages 12 to 17): Transitioning to Adult Care

What Is Trazodone and Why Is It Used in Adolescents?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors and weakly inhibits the serotonin transporter. Clinicians prescribe it off-label in adolescents primarily for insomnia and as an adjunct in major depressive disorder (MDD). The FDA has never granted it a pediatric indication, but real-world prescribing in the 12 to 17 age group is common.

Mechanism and Pharmacology

At low doses (25 to 75 mg), trazodone's sedative properties dominate because 5-HT2A and histamine H1 antagonism occur at lower receptor occupancy thresholds than serotonin reuptake inhibition. This pharmacodynamic profile makes it appealing for sleep disturbance without the dependency risk seen with benzodiazepines or Z-drugs.

A 2019 review in the Journal of Child and Adolescent Psychopharmacology noted that trazodone's sedative dose range in adolescents typically falls between 25 mg and 100 mg at bedtime, well below the antidepressant doses used in adults. Prescribers should document the specific therapeutic intent clearly in the medical record before any care transfer [1].

Off-Label Use Field

No large randomized controlled trials have established efficacy or safety specifically in the 12 to 17 cohort for either insomnia or MDD. The Pediatric Research Equity Act (PREA) did not compel a pediatric study for trazodone given its pre-FDAMA approval status. Clinicians rely on adult trial data and smaller observational series when making dosing decisions for this population [2].

FDA Black-Box Warning: Suicidality in Patients Under 25

The FDA's black-box warning on all antidepressants mandates heightened monitoring for suicidal thinking and behavior in patients under 25 years old. This applies directly to every adolescent on trazodone.

What the Warning Requires

The 2004 FDA public health advisory, later formalized in labeling updates, requires that patients aged <18 be seen weekly for the first four weeks, every two weeks for weeks 5 to 8, and then at 12 weeks after starting or changing the dose of any antidepressant, including trazodone [3].

A direct quote from FDA prescribing information states: "Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior" [3].

During a care transition, this schedule can fracture. The departing pediatric provider may close the chart, and the incoming adult provider may not recognize that the monitoring clock needs to continue or restart.

Risk Period at Transition

The transition itself can be a destabilizing event. Adolescents moving from a familiar pediatric psychiatrist to an unfamiliar adult provider may experience anxiety, medication non-adherence, or dose self-adjustment. A 2016 study in Psychiatric Services found that 39% of youth with serious mental illness experienced a gap in outpatient care of 90 days or more during the transition to adult services [4]. A gap of that length while on an antidepressant with a black-box warning is clinically significant.

Dosing: Adolescent Range vs. Adult Range

Dose escalation between the pediatric and adult ranges is not automatic at age 18. Prescribers must re-evaluate based on weight, hepatic function, concomitant medications, and therapeutic goals.

Adolescent Off-Label Dosing

Off-label adolescent dosing for insomnia generally begins at 25 mg at bedtime and may be titrated to 50 to 100 mg. For adjunctive depression treatment, doses of 50 to 150 mg per day are described in case series and small open-label reports. No established weight-based formula exists; prescribers extrapolate from adult data.

Adult Labeled Dosing

FDA-approved adult dosing for MDD starts at 150 mg per day in divided doses, with increments of 50 mg every three to four days, up to a maximum of 400 mg per day in outpatients and 600 mg per day in inpatients [3]. The gap between a typical adolescent bedtime dose of 50 mg and a starting adult antidepressant dose of 150 mg is large.

Managing the Dose Transition

When an 18-year-old arrives at an adult provider having taken trazodone 75 mg nightly for sleep, the adult prescriber faces a choice: continue the current dose for the same indication, retitrate upward if MDD is also a diagnosis, or evaluate whether a different agent now better fits adult treatment guidelines. The American Psychiatric Association practice guideline for MDD recommends SSRIs or SNRIs as first-line pharmacotherapy in adults, positioning trazodone as a second-line or adjunctive agent [5]. That context should be part of the handoff conversation.

Drug Interactions and Safety Considerations Specific to This Age Group

Trazodone carries several interaction risks that are especially relevant as adolescents gain autonomy over their own medications and may begin using substances or starting new prescriptions without parental oversight.

CYP3A4 Interactions

Trazodone is metabolized primarily by CYP3A4. Strong inhibitors of this enzyme, such as clarithromycin, ketoconazole, and ritonavir, can increase trazodone plasma concentrations substantially. Adolescents starting hormonal contraceptives or HIV pre-exposure prophylaxis medications at the transition age should have their trazodone dose reviewed [2].

Strong CYP3A4 inducers, including carbamazepine and rifampin, may reduce trazodone levels to sub-therapeutic concentrations. Carbamazepine is itself sometimes used in adolescent bipolar disorder, making this a common co-prescribing scenario to flag.

Serotonin Syndrome Risk

Combining trazodone with other serotonergic agents, including SSRIs, SNRIs, tramadol, linezolid, or recreational MDMA, raises the risk of serotonin syndrome. Adolescents may not disclose recreational substance use to a new adult provider. Screening for this at every visit during transition is appropriate.

Priapism

Trazodone carries a rare but serious risk of priapism in males, occurring in approximately 1 in 6,000 patients based on post-marketing data cited in FDA labeling [3]. Male adolescents transitioning to adult care should be explicitly counseled that this risk persists and that any erection lasting more than four hours requires emergency evaluation.

QTc Prolongation

Trazodone produces modest QTc prolongation. A meta-analysis published in Psychopharmacology in 2021 found a mean QTc increase of approximately 4.5 ms at standard therapeutic doses [6]. This is generally considered low-risk in isolation but becomes relevant when combined with other QTc-prolonging agents or in patients with underlying cardiac conditions. A baseline ECG is reasonable before continuing trazodone in a new adult care setting if one has not been done recently.

Monitoring Protocol During Transition

Structured monitoring is the single most effective way to prevent adverse outcomes during care transfer.

Recommended Monitoring Schedule

Following the FDA antidepressant labeling requirements, any dose change or restart of trazodone at the transition visit should trigger a fresh monitoring schedule: weekly for four weeks, biweekly for two months, and monthly thereafter [3]. If the dose is being continued without change and the patient is stable, the adult provider should still confirm the patient's current mental status and sleep quality at the first visit.

Laboratory monitoring for trazodone does not require routine serum levels in most patients. However, a complete metabolic panel to assess hepatic function is reasonable given CYP3A4 metabolism, particularly if the patient has gained weight or started new hepatically-metabolized medications.

Standardized Transfer Documentation

The American Academy of Pediatrics recommends a portable medical summary for all adolescents transitioning to adult care, covering diagnoses, current medications with doses and start dates, allergies, and contact information for prior providers [7]. For adolescents on trazodone, this summary should also include:

• The original indication (insomnia, MDD, or both)
• Current dose and any prior dose changes
• History of any suicidal ideation or behavior while on the medication
• Most recent PHQ-A (Patient Health Questionnaire, Adolescent) score
• Results of any prior ECG

Mental Health Screening Tools

The PHQ-9 is validated for adults; the PHQ-A for adolescents. At the transition visit, switching from PHQ-A to PHQ-9 is appropriate. The Patient Health Questionnaire-9 has a sensitivity of 88% and specificity of 88% for MDD in adult primary care settings according to the original Spitzer et al. Validation study [8]. Both tools should be scored and documented before the handoff to give the incoming provider a baseline.

Transition Models and Best-Practice Frameworks

Transition is not a single appointment. Structured programs produce better continuity than informal handoffs.

Got Transition Program

Got Transition (a program of the National Alliance to Advance Adolescent Health, supported by the Maternal and Child Health Bureau) publishes the Six Core Elements of Health Care Transition, a free framework adapted for both pediatric and adult practices. The Six Core Elements include developing a transition policy, tracking transition readiness, planning the transition, transferring care, confirming completion, and completing the transition [9]. Prescribers managing trazodone in this age group should use or adapt this framework.

Joint Visits

Some programs schedule a single overlapping visit where the pediatric and adult providers both meet with the patient. This format, sometimes called a "warm handoff," allows medication reconciliation in real time. A 2020 study in Pediatrics found that youth with mental health conditions who received a structured transition with warm handoff had significantly lower rates of care discontinuation at six months than those with standard referral alone [10].

Timing the Transition

Most programs target transition at age 18. Some developmental or behavioral health programs extend coverage to age 21, particularly for patients with comorbid intellectual disability or autism spectrum disorder. For those patients, the trazodone use-case may skew toward sleep management in the context of ASD-related insomnia, which has its own evidence base.

Special Populations Within the 12 to 17 Transition Cohort

Not every adolescent transitioning out of pediatric care has the same risk profile.

Adolescents With Comorbid Substance Use

Substance use disorders often emerge or escalate in late adolescence. Alcohol, cannabis, and stimulant use can interact with trazodone's CNS-depressant and serotonergic properties. The 2021 SAMHSA National Survey on Drug Use and Health reported that 11.3% of adolescents aged 12 to 17 used illicit drugs in the past month [11]. Trazodone prescribers should screen with a validated tool such as the CRAFFT-2 at every visit and document findings in the transfer summary.

Adolescents With Autism Spectrum Disorder

Sleep disturbance affects 50 to 80% of children and adolescents with ASD. Trazodone is used in this population largely because behavioral interventions alone are insufficient for moderate to severe insomnia and melatonin has limited efficacy in some patients. The transition for this sub-group should involve a developmental medicine specialist or psychiatrist familiar with ASD in adults, as adult ASD care resources are significantly more limited than pediatric ones.

Female Adolescents Starting Hormonal Medications

Young women transitioning to adult care frequently start combined oral contraceptives or other hormonal therapies. Ethinyl estradiol can weakly inhibit CYP3A4, potentially raising trazodone exposure. The clinical magnitude is modest, but new hormonal prescriptions should prompt a quick drug-interaction review at the transition visit.

Patient and Family Counseling at Transition

Counseling the patient and their family, or caregiver, is a specific clinical task at the transition visit, not an afterthought.

Key Points to Cover

Patients and families should understand that trazodone does not cure depression or insomnia; it manages symptoms. Stopping abruptly is generally safe given trazodone's low physical-dependence profile, but abrupt discontinuation of any antidepressant in a patient with MDD risks relapse. Patients should be told explicitly who to call if symptoms worsen, who manages prescription refills during the handoff period, and how to access emergency mental health services.

Written Instructions

A written or printed medication summary, not just a portal message, improves adherence during transitions. The Joint Commission's National Patient Safety Goal on medication reconciliation requires that providers document and communicate complete medication lists at transitions of care [12]. A single printed page listing trazodone dose, indication, prescriber contact, and red-flag symptoms to watch for satisfies this requirement.

Regulatory and Prescribing Authority Considerations

Clinicians treating 17-year-olds who turn 18 mid-treatment face a brief regulatory ambiguity. Prescriptions written for a minor in some states require parental consent; prescriptions written for an adult do not. Most electronic health record systems auto-update patient age, but prescribers should confirm that their state's mental health consent laws do not require any additional documentation at the legal transition to adulthood.

The FDA's MedWatch program accepts adverse event reports for off-label trazodone use in adolescents [3]. Any serious adverse event, including a suicidality-related hospitalization, should be reported both to MedWatch and documented in the patient's chart before the transition is complete.